FDA Adverse Event Injury Summary report: N

HEMOBLAST BELLOWS

MDR report key: 12224555 · Received July 26, 2021

Report

Report Number
3007702492-2021-00001
Event Type
Injury
Date Received
July 26, 2021
Date of Event
June 18, 2021
Report Date
July 23, 2021
Manufacturer
BIOM'UP FRANCE SAS
Product Code
PMX
UDI-DI
03760193182705
PMA / PMN Number
P170012
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
CA, US
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

SURGEON PERFORMED BREAST RECONSTRUCTION WITH EXPANDER. HEMOBLAST WAS APPLIED AFTER TISSUE REMOVAL AND HEMOSTASIS WAS ACHIEVED. THE SURGEON REPORTED THAT EXCESS HEMOBLAST WAS NOT REMOVED. THE PRODUCT IFU INSTRUCTS THAT ONCE HEMOSTASIS IS ACHIEVED, EXCESS HEMOBLAST SHOULD BE REMOVED FROM THE APPLICATION SITE BY IRRIGATION AND ASPIRATION.

Description of Event or Problem · 1

TWO DAYS AFTER BREAST RECONSTRUCTION SURGERY, PATIENT WAS BROUGHT BACK TO OR TO EVACUATE A 400CC SEROMA. SEROMA FORMATION WAS ATTRIBUTED TO CLOGGED DRAIN. SURGEON REPORTED THE DRAIN WAS CLOGGED FROM THE HEMOBLAST.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1121505 HEMOBLAST BELLOWS HEMOSTATIC AGENT PMX BIOM'UP FRANCE SAS BQF02 03760193182705

Patients

Seq Age Sex Outcome Treatment
1 Required Intervention KCI PREVENA RESTOR BELLA-FORM INCISION MANAGEMENT